Updated

A report from congressional Democrats found that President Trump's pharmaceutical stock holdings grew from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million at the end of 2025. The report alleged that Trump increased investments in drugmakers that had been given Medicare exemptions, raising questions about potential conflicts of interest. The findings fuel ongoing scrutiny of Trump's financial holdings and their potential relationship to his policy decisions.